Mothers against decapentaplegic homolog 3 (SMAD3) mRNA (SMAD3 mRNA)

SMAD3 mRNA encodes the Mothers against decapentaplegic homolog 3 protein, a key intracellular mediator of the Transforming Growth Factor-beta (TGF-beta) signaling pathway [UniProt; NCBI Gene]. Upon activation by TGF-beta receptors, the resulting SMAD3 protein is phosphorylated and forms a complex with SMAD4 to regulate the transcription of genes involved in cell proliferation, differentiation, and apoptosis [Cell, 2000]. This pathway is essential for maintaining tissue homeostasis and regulating the production of extracellular matrix components [International Journal of Experimental Pathology, 2004]. Dysregulation of SMAD3 expression or activity is strongly associated with the development of chronic fibrotic diseases in the lungs, kidneys, and liver [Journal of Clinical Investigation, 2003]. In oncology, SMAD3 plays a dual role, acting as a tumor suppressor in early stages but promoting metastasis and epithelial-mesenchymal transition (EMT) in advanced cancers [Cell, 2000]. Targeting SMAD3 mRNA using antisense oligonucleotides (ASOs) or small interfering RNAs (siRNAs) is an emerging therapeutic strategy to selectively reduce SMAD3 protein levels [International Journal of Experimental Pathology, 2004]. These RNA-based therapies aim to block the pathological fibrotic response and inhibit tumor progression without the broad toxicity associated with global TGF-beta inhibition [Cell, 2000]. However, therapeutic development faces challenges such as ensuring efficient delivery to target tissues and avoiding adverse effects on immune regulation and wound healing [UniProt; Journal of Clinical Investigation, 2003].

Other names

SMAD family member 3 mRNAMADH3 mRNAJV15-2 mRNAHSPC193 mRNAMAD homolog 3 mRNA

Antisense inhibition or RNA interference leading to mRNA degradation and reduced protein translation